Board of Directors
Dr James Field, Founder & CEO
James completed his EPSRC-funded PhD at Imperial College London where he developed a platform for targeted drug delivery using re-engineered protein nanocages. Prior to his PhD, James completed a BSc in Biology with Microbiology (1st Class) and an MRes in Systems and Synthetic Biology (Distinction), at Imperial College London.
James is an active member of the synthetic biology community having participated in the iGEM competition both as an undergraduate (2009), advisor (2011) and judge (2016).
In 2017, James was awarded the BBSRC Innovator of the Year award for early career impact. In 2018, James was featured on Forbes' 30 Under 30 list for Science & Healthcare. James is also a fellow of the prestigious Synthetic Biology Leadership Excellence Accelerator Program (LEAP).
Outside of work, James enjoys time with his daughter, reading science fiction and drinking loose leaf Earl Grey tea.
Leila Zegna, Investor Director
Leila is a founding partner at Kindred Capital and acts as Investor Director at LabGenius.
She is both an investor and an entrepreneur, with over a decade of operating experience in technology businesses across three continents.
Leila holds an MBA from Harvard Business School, as well as a BS in Mathematics and Philosophy from Yale University. Leila was also part of the founding team of GenapSys, a DNA sequencing company that raised over $50 million.
Harry Rickerby, Platform Architect
Harry is responsible for overseeing the development of LabGenius' technology stack.
Harry studied at Imperial College, attaining an MRes in Systems and Synthetic Biology (Distinction).
Harry was LabGenius’ first employee, co-inventing the company's foundational library synthesis technology and applying this to numerous directed evolution projects. Harry also serves as a technical advisor to the EPSRC-funded Portabolomics project at Newcastle University.
Harry loves kayaking, hiking in the mountains, noodling on his guitar and home-brewing.